Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03132623
Other study ID # JXQF-XYP-1609
Secondary ID
Status Recruiting
Phase Phase 4
First received April 11, 2017
Last updated April 27, 2017
Start date December 1, 2016
Est. completion date June 1, 2018

Study information

Verified date April 2017
Source Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Contact Lang Lv
Phone +86 010-84682600
Email bjlll@qfyy.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multicenter, randomized, double-blind, placebo-controlled, phase 4 clinical trial to evaluate the efficacy and safety of andrographolide sulfonate in patients with acute bronchitis


Description:

The patient after passing the screening, with the ratio of 1:1, were randomly assigned to experimental group or control group. Experimental group: Xiyanping injection(andrographolide sulfonate) 10-20ml/d, with 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops. Control group: Xiyanping injection simulation(0.9% Sodium Chloride Injection) 10-20ml/d, The treatment method is the same as the experimental group. Treatment cycle: less than 7 days (the longest period of treatment is 7 days, if the clinical symptoms were relieved in the treatment, patients were stoped treatment).


Recruitment information / eligibility

Status Recruiting
Enrollment 144
Est. completion date June 1, 2018
Est. primary completion date December 30, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- 1.18-65 years, males or females;

- 2.patients met the acute bronchitis diagnosis;

- 3.patients'all symptoms (including cough) appeared no longer than 72 h before inclusion to the trial;

- 4.patients compliance is good, written informed consent was obtained from all participants before the study.

Exclusion Criteria:

- 1.Patients had a history of andrographolide sulfonate or andrographolide allergy.

- 2.pregnancy, lactation, and absence of contraception in women of fertile age.

- 3.Judging by the researchers, Past or present illness of patients may affect to participate in the trial or affect the outcome of the study, including cardio-pulmonary diseases, malignant diseases, autoimmune diseases, hepatorenal disease, blood diseases, nervous system diseases, immune system diseases and endocrine diseases.

- 4.After checking, Patients with pulmonary tuberculosis, bronchial asthma, bronchial pneumonia, bronchiectasis, pneumoconiosis, silicosis, lung cancer, pulmonary infiltration or other allergic respiratory diseases and other chronic lung diseases

- 5.Patients using systemic steroids or other immunosuppressive therapy

- 6.Patients with severe cardiopulmonary dysfunction, abnormal liver and kidney function, blood system diseases.

- 7.Patients are alcohol (daily drink alcoholic wine is more than 40g) or drug abuse or drug addicts in the past year.

- 8.Patients were participated in any study of drug trials in the last 30 days.

- 9.According to the researchers' judgment, anyone who are not suitable for the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
andrographolide sulfonate
Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
andrographolide sulfonate simulation
Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.

Locations

Country Name City State
China The First Affiliated Hospital of Nanchang University Nanchang Jiangxi

Sponsors (1)

Lead Sponsor Collaborator
Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary cured rate clinical symptoms(fever, cough) and signs(pulmonary rales) totally disappear, the period of lab tests return to normal is recorded less than 7 days
Secondary effective time window days range from treatment is received to the effectiveness is observed, and symptoms disappear less than 7 days
Secondary time from admission to recovery of fever In the absence of other antipyretic drugs, the time from Xiyangping injection beganning to use to Axillary temperature below 37.5? , and last more than 24 hours without fever. less than 7 days
Secondary the incidence of complications Such as, the incidence of Pneumonia, chronic bronchitis, bronchiectasis,and so on. less than 7 days
Secondary days of Anti infective Drugs use oral anti infective Drugs use days and intravenous Anti infective Drugs use days are recorded less than 7 days
Secondary number of participants with treatment-related adverse events the total incidence of adverse events,the incidence of adverse events associated with Xiyanping injection, the incidence of patients with grade 3 through grade 4 adverse events that are related to study drug, graded according to NCI-CTC V4.0 .
Observe and record all adverse events and serious adverse events, including physical examination, vital signs, laboratory tests (Hematology, blood biochemistry, urine routine, stool routine), ECG changes and so on.
less than 7 days
See also
  Status Clinical Trial Phase
Completed NCT03711292 - Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings N/A
Not yet recruiting NCT03517215 - The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program N/A
Completed NCT01420445 - Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis Phase 2
Completed NCT00360464 - A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases Phase 3
Completed NCT05344638 - A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis Phase 3
Completed NCT06457269 - Evaluating the Potential of Large Language Models for Respiratory Disease Consultations N/A
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT03827590 - Clinical Trials to Assess the Efficacy and Safety of HLIM Phase 3
Completed NCT02792946 - Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis Phase 3
Completed NCT01875757 - Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life Phase 3
Recruiting NCT04252963 - Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase) Phase 4
Recruiting NCT06411925 - The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients Phase 4
Completed NCT01416480 - Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher Phase 3
Enrolling by invitation NCT05916768 - Management of Acute Bronchitis With Pelargonium Sidoides Extract N/A
Completed NCT03309800 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients Phase 2
Completed NCT02250027 - A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on) Phase 2
Not yet recruiting NCT03310385 - Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis Phase 2
Completed NCT03654196 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients Phase 3
Completed NCT03011515 - Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
Completed NCT02045394 - Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study N/A